200 related articles for article (PubMed ID: 21506597)
21. [Perhaps an explanation for the therapeutic escape of prostate cancer treated with antiandrogens].
Jeanteur P
Bull Cancer; 2000 Jul; 87(7-8):524-5. PubMed ID: 10969205
[No Abstract] [Full Text] [Related]
22. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Goto T; Ohta K; Fujii S; Ohta S; Endo Y
J Med Chem; 2010 Jul; 53(13):4917-26. PubMed ID: 20521823
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
24. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.
Sundén H; Holland MC; Poutiainen PK; Jääskeläinen T; Pulkkinen JT; Palvimo JJ; Olsson R
J Med Chem; 2015 Feb; 58(3):1569-74. PubMed ID: 25646649
[TBL] [Abstract][Full Text] [Related]
26. Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
Nique F; Hebbe S; Triballeau N; Peixoto C; Lefrançois JM; Jary H; Alvey L; Manioc M; Housseman C; Klaassen H; Van Beeck K; Guédin D; Namour F; Minet D; Van der Aar E; Feyen J; Fletcher S; Blanqué R; Robin-Jagerschmidt C; Deprez P
J Med Chem; 2012 Oct; 55(19):8236-47. PubMed ID: 22957947
[TBL] [Abstract][Full Text] [Related]
27. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands.
Wakabayashi K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2005 Apr; 13(8):2837-46. PubMed ID: 15781394
[TBL] [Abstract][Full Text] [Related]
28. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs.
Kumar S; Jaiswal B; Kumar S; Negi S; Tyagi RK
Biochem Pharmacol; 2010 Oct; 80(7):964-76. PubMed ID: 20599793
[TBL] [Abstract][Full Text] [Related]
29. Development of a benzopyran-containing androgen receptor antagonist to treat antiandrogen-resistant prostate cancer.
Oh S; Nam HJ; Park J; Beak SH; Park SB
ChemMedChem; 2010 Apr; 5(4):529-33. PubMed ID: 20135667
[No Abstract] [Full Text] [Related]
30. Androgens and pharmacology.
Haendler B
Andrologia; 2005 Dec; 37(6):213-5. PubMed ID: 16336252
[No Abstract] [Full Text] [Related]
31. A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells.
Tian HY; Yuan XF; Jin L; Li J; Luo C; Ye WC; Jiang RW
Chem Biol Interact; 2014 Jan; 207():16-22. PubMed ID: 24211617
[TBL] [Abstract][Full Text] [Related]
32. Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
J Med Chem; 2021 Aug; 64(15):11045-11062. PubMed ID: 34269581
[TBL] [Abstract][Full Text] [Related]
33. Advances in the computational development of androgen receptor antagonists.
Hu X; Chai X; Wang X; Duan M; Pang J; Fu W; Li D; Hou T
Drug Discov Today; 2020 Aug; 25(8):1453-1461. PubMed ID: 32439609
[TBL] [Abstract][Full Text] [Related]
34. Targeting the androgen receptor with steroid conjugates.
Levine PM; Garabedian MJ; Kirshenbaum K
J Med Chem; 2014 Oct; 57(20):8224-37. PubMed ID: 24936953
[TBL] [Abstract][Full Text] [Related]
35. In silico investigations of anti-androgen activity of polychlorinated biphenyls.
Li X; Ye L; Wang X; Shi W; Liu H; Qian X; Zhu Y; Yu H
Chemosphere; 2013 Aug; 92(7):795-802. PubMed ID: 23664479
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical androgen receptor regulation by small molecule enantiomers.
Patsch K; Liu C; Zapotoczny G; Sun Y; Sura H; Ung N; Sun RX; Haliday B; Yu C; Aljehani M; Lee JSH; Kashemirov BA; Agus DB; McKenna CE; Ruderman D
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33741738
[TBL] [Abstract][Full Text] [Related]
37. [Androgen receptors in target tissues and tumors].
Sharoukhova KS
Vopr Onkol; 1979; 25(5):75-80. PubMed ID: 88807
[No Abstract] [Full Text] [Related]
38. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor modulators: a marriage of chemistry and biology.
McEwan IJ
Future Med Chem; 2013 Jun; 5(10):1109-20. PubMed ID: 23795968
[TBL] [Abstract][Full Text] [Related]
40. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
